NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Short Interest Up 29.4% in April

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 3,248,961 shares, an increase of 29.4% from the March 31st total of 2,511,228 shares. Approximately 10.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 703,102 shares, the days-to-cover ratio is presently 4.6 days.

NRx Pharmaceuticals Price Performance

NRx Pharmaceuticals stock traded up $0.07 during midday trading on Thursday, reaching $2.98. The stock had a trading volume of 957,765 shares, compared to its average volume of 1,044,708. The firm’s fifty day simple moving average is $2.22 and its two-hundred day simple moving average is $2.33. NRx Pharmaceuticals has a twelve month low of $1.62 and a twelve month high of $3.84. The firm has a market cap of $98.55 million, a price-to-earnings ratio of -2.14 and a beta of 1.83.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Monday, March 23rd. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.28. The firm had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $7.53 million. As a group, sell-side analysts predict that NRx Pharmaceuticals will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. AdvisorShares Investments LLC lifted its stake in NRx Pharmaceuticals by 28.2% in the 1st quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock worth $896,000 after acquiring an additional 92,463 shares in the last quarter. Anson Funds Management LP grew its stake in NRx Pharmaceuticals by 50.3% during the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after acquiring an additional 1,018,853 shares in the last quarter. State Street Corp grew its stake in NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after acquiring an additional 10,700 shares in the last quarter. Commonwealth Equity Services LLC acquired a new position in shares of NRx Pharmaceuticals in the 4th quarter valued at about $994,000. Finally, Geode Capital Management LLC increased its holdings in shares of NRx Pharmaceuticals by 17.8% in the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after purchasing an additional 33,004 shares during the period. 4.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. D. Boral Capital reiterated a “buy” rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday, April 20th. HC Wainwright restated a “buy” rating and issued a $45.00 target price on shares of NRx Pharmaceuticals in a report on Monday. BTIG Research reaffirmed a “buy” rating and set a $25.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday, March 24th. Zacks Research raised NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Finally, Ascendiant Capital Markets increased their price target on NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research report on Monday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.25.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.